$BTSG

ROUSSEAU JON B sold $7.6M of BTSG (indirect holdings)

ROUSSEAU JON B (See Remarks) sold 130,000 indirectly-held shares of BrightSpring Health Services, Inc. (BTSG) at $58.75 ($7.64M total) on 2026-06-05.

Original reporting
SEC EDGAR · ROUSSEAU JON B
Published Jun 5, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BTSG
Bearish
medium confidence
Mentioned
$BTSG
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BTSGBearishLow
01

Why it matters

The disclosure provides a fresh, company-specific sentiment datapoint (insider selling) but lacks any operational or financial trigger that would typically drive a re-rating.

02

Market read

Traders may mark the stock slightly lower on insider-selling optics, but the event is unlikely to be a standalone fundamental catalyst.

03

What to watch

The filing notes holdings after transaction are 0 shares, but it does not quantify prior total holdings, sale rationale, or any concurrent buys.

Relevance 7/10Novelty 6/10Timing: same-day disclosure (June 5)

Background

This is an SEC Form 4 insider transaction (officer/director) reported on EDGAR for BrightSpring Health Services, Inc.

Company-level read

Ticker impact

$BTSGBearishMedium confidence
Context

BrightSpring Health Services disclosed an officer/director open-market sale of 130,000 shares at $58.75 on June 5 via Form 4.

Expected impact

Near-term: modest downside bias possible on sentiment; fundamental impact unlikely from a single Form 4.

Evidence & confidence

The filing is a concrete, same-day datapoint for BTSG, but insider sales are often non-informational and the article provides no earnings/operational catalyst.

Market effects

Limited read-across; insider-sale disclosures rarely change sector fundamentals without accompanying company-specific catalysts.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio management; without a stated 10b5-1 plan, it still may not signal deteriorating fundamentals.

Key entities

  • BrightSpring Health Services, Inc.

    Subject of the insider transaction; officer/director ROUSSEAU JON B sold 130,000 shares at $58.75.

  • ROUSSEAU JON B

    Officer/director who executed the open-market sale; holdings after transaction reported as 0 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BTSGMedAI 8/10

BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue?

BrightSpring Health Services (BTSG) stock has risen 59% YTD, outperforming industry and S&P 500. Q2 2026 revenues grew 23% to $3.9B, adjusted EBITDA up 44%. Growth driven by Specialty Pharmacy and Provider Services, with AI/automation improving efficiency. Leverage reduced to 2.15x. 2026 EPS estimates raised to $1.78 (78% growth). Risks include execution challenges and reimbursement pressures.

$BTSGMedAI 9/10

BrightSpring Health (BTSG) Q2 2026 Earnings Call Transcript

BrightSpring Health Services (BTSG) reported Q2 2026 net revenue of $3.873B, up 23%, and adjusted EBITDA of $205.5M, up 44.2%, with adjusted EPS of $0.45. FY2026 guidance raised to $15.1B-$15.425B revenue and $820M-$845M adjusted EBITDA. Net debt was $1.7B (2.15x leverage).

$BTSGMed

5 Revealing Analyst Questions From BrightSpring Health Services’s Q2 Earnings Call

BrightSpring Health Services (BTSG) reported Q2 revenue of $3.87B vs $3.66B expected and adjusted EPS of $0.45 vs $0.40, with adjusted EBITDA of $205.5M. The company raised full-year revenue guidance to $15.26B and EBITDA guidance to $832.5M. Management cited 30% Specialty and Infusion revenue growth and 31% script growth, while Home and Community Pharmacy faced customer exits and regulatory headwinds.

$BTSGMedAI 8/10

BTSG Raises 2026 Guidance as Specialty and Home Health Drive Growth

BrightSpring Health Services (BTSG) beat Q2 expectations with adjusted EPS of 45 cents (21.6% above consensus) and revenue of $3.87B (+23% YoY). It raised 2026 guidance to $15.10-$15.425B revenue and $820-$845M adjusted EBITDA. Specialty and infusion grew 30.1% and home health revenues rose 30.3%, while pharmacy fell 8% due to IRA impacts.